Literature DB >> 22949570

Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo.

Taneisha S Buchanan1, Lisa Sanderson Cox, Janet L Thomas, Nicole L Nollen, Carla J Berg, Matthew S Mayo, Jasjit S Ahluwalia.   

Abstract

INTRODUCTION: Psychoactive effects of smoking cessation medi cations such as bupropion may allow participants in smoking cessation clinical trials to correctly guess their treatment assignment at rates greater than chance. Previous research has found an association between perceived treatment assignment and smoking cessation rates among moderate to heavy smokers (≥ 10 cigarettes per day [cpd]) in two bupropion clinical trials.
METHODS: The aim of this study was to determine the impact of perceived treatment assignment on end-of-treatment cotinine-verified smoking abstinence at Week 7 and Week 26 among African American light smokers (≤ 10 cpd) enrolled in a double-blind, placebo-controlled study of bupropion. Participants (n = 390) included in this study reported their perceived treatment assignment on the end-of-treatment (Week 7) survey.
RESULTS: Participants were predominantly female (63.1%), 48.1 years of age (SD = 11.2), and smoked an average of 8 cpd (SD = 2.5). Participants given bupropion were more likely to correctly guess their treatment assignment (69%; 140/203) than those assigned to placebo (51.3%; 96/187) (p < .0001). After adjusting for treatment condition, participants who perceived assignment to bupropion versus placebo were not more likely to be abstinent than those who perceived assignment to placebo at Week 7 or at Week 26. The interaction between treatment and perceived treatment assignment was also nonsignificant.
CONCLUSIONS: Consistent with two previous studies testing bupropion, participants assigned to bupropion were more likely to correctly guess their treatment assignment than those assigned to placebo. However, in contrast to previous studies with heavier smokers, perceived treatment assignment did not significantly impact cotinine-verified abstinence in light smokers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949570      PMCID: PMC3611997          DOI: 10.1093/ntr/nts143

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  16 in total

1.  Mediating mechanisms for the impact of bupropion in smoking cessation treatment.

Authors:  Caryn Lerman; David Roth; Vyga Kaufmann; Janet Audrain; Larry Hawk; Aiyi Liu; Ray Niaura; Leonard Epstein
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

Review 2.  The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials.

Authors:  Marc Mooney; Thom White; Dorothy Hatsukami
Journal:  Addict Behav       Date:  2004-06       Impact factor: 3.913

3.  Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Authors:  Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia
Journal:  J Natl Cancer Inst       Date:  2012-01-25       Impact factor: 13.506

Review 4.  A comprehensive review of the placebo effect: recent advances and current thought.

Authors:  Donald D Price; Damien G Finniss; Fabrizio Benedetti
Journal:  Annu Rev Psychol       Date:  2008       Impact factor: 24.137

5.  Nicotine lozenge efficacy in light smokers.

Authors:  Saul Shiffman
Journal:  Drug Alcohol Depend       Date:  2005-03-07       Impact factor: 4.492

6.  The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design.

Authors:  Jasjit S Ahluwalia; Kolawole Okuyemi; Nicole Nollen; Won S Choi; Harsohena Kaur; Kim Pulvers; Matthew S Mayo
Journal:  Addiction       Date:  2006-06       Impact factor: 6.526

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

8.  The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers.

Authors:  Janet L Thomas; Hongfei Guo; Ian M Lynam; Joshua N Powell; Kolawole S Okuyemi; Carrie A Bronars; Jasjit S Ahluwalia
Journal:  J Gen Intern Med       Date:  2008-06-29       Impact factor: 5.128

9.  Blindness and the validity of the double-blind procedure.

Authors:  J R Hughes; D Krahn
Journal:  J Clin Psychopharmacol       Date:  1985-06       Impact factor: 3.153

10.  Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation.

Authors:  Robert A Schnoll; Leonard Epstein; Janet Audrain; Raymond Niaura; Larry Hawk; Peter G Shields; Caryn Lerman; E Paul Wileyto
Journal:  J Subst Abuse Treat       Date:  2007-06-27
View more
  2 in total

1.  Perceived medication assignment during a placebo-controlled laboratory study of varenicline: temporal associations of treatment expectancies with smoking-related outcomes.

Authors:  John B Correa; Bryan W Heckman; Nicole S Marquinez; David J Drobes; Marina Unrod; Richard G Roetzheim; Thomas H Brandon
Journal:  Psychopharmacology (Berl)       Date:  2014-01-10       Impact factor: 4.530

2.  Antidepressants for smoking cessation.

Authors:  Seth Howes; Jamie Hartmann-Boyce; Jonathan Livingstone-Banks; Bosun Hong; Nicola Lindson
Journal:  Cochrane Database Syst Rev       Date:  2020-04-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.